Cell Press Reviews: Cancer Therapeutics

Cell Press Reviews: Cancer Therapeutics

1st Edition - December 10, 2013

Write a review

  • Editor: Cell Press
  • eBook ISBN: 9780127999173
  • Paperback ISBN: 9780124201927

Purchase options

Purchase options
DRM-free (PDF, Mobi, EPub)
Available
Sales tax will be calculated at check-out

Institutional Subscription

Free Global Shipping
No minimum order

Description

Cell Press Reviews: Cancer Therapeutics informs, inspires, and connects cancer researchers at all stages in their careers with timely, comprehensive reviews written by leaders in the field and curated by Cell Press editors. The publicatio offers a broad view of some of the most compelling topics in cancer therapeutics including: Genetic approaches for personal oncology Targeting epigenetic dysregulation and protein interaction networks Vaccines and antibodies in cancer immunotherapy Tumor heterogeneity and chemotherapy resistance Tumor associated macrophages in anticancer treatment Contributions come from leading voices in the field, including:- Daniel A. Haber, Director of Massachusetts General Hospital Cancer Center and Professor at Harvard Medical School- Tony Kouzarides, Professor at the University of Cambridge, Deputy Director of the Wellcome Trust/Cancer Research UK Gurdon Institute, and a founder of the cancer drug discovery company Chroma Therapeutics- Charles L. Sawyers, Chair of the Human Oncology and Pathogenesis Program at Memorial Sloan Kettering Cancer Center, President of the American Association for Cancer Research, member of the presidentially appointed National Cancer Advisory Board, and recipient of the 2013 Breakthrough Prize in Life Sciences Cell Press Reviews: Cancer Therapeutics is part of the Cell Press Reviews series, which features reviews published in Cell Press primary research and Trends reviews journals.

Key Features

  • Provides timely, comprehensive articles on a wide range of topics in cancer therapeutics
  • Offers insight from experts on genetic, molecular, and cellular aspects of cancer therapy
  • Features reviews on basic science advances translated into drug discovery and therapeutic approaches
  • Includes articles originally published in Cell, Cancer Cell, Trends in Genetics, Trends in Molecular Medicine, and Trends in Pharmacological Sciences

Readership

Academic, medical researchers, and students in cancer biology, and cancer prevention/therapeutics, including cell biologists, biological chemists, geneticists, pharmacologists, oncologists, and radiation oncologists.

Table of Contents

  • About Cell Press

    Contributors

    Preface

    Chapter 1. The Evolving War on Cancer

    Acknowledgments

    Summary

    Introduction

    Breaking the Cancer War Stalemate

    Drawing from Somatic Cancer Genetics to Find Therapeutic Targets

    Challenging Medicinal Chemistry to Design New Classes of Inhibitors

    Redesigning Cancer Clinical Trials: Genotype First, Monitor in Real Time

    The Next Steps in the War on Cancer

    References

    Chapter 2. Can We Deconstruct Cancer, One Patient at a Time?

    Acknowledgments

    Summary

    Cancer Treatment in the Age of Omics

    Cancer as a Black Box

    Deconstructing Cancer, One Patient at a Time

    The Road Ahead

    Concluding Remarks

    References

    Chapter 3. The Genetic Basis for Cancer Treatment Decisions

    Acknowledgments

    Summary

    Introduction

    Framework Requirements for Evaluating the Genetic Basis for Cancer Treatment

    Patient Recruitment and Informed Consent

    Tissue Requirements: Quantity, Quality, Processing, and Timing

    Genomic Technologies and Data Management

    Reporting Data to Clinicians and Patients

    Monitoring and Evaluating the Utility of Clinical Genomics

    Data Sharing

    Implications for Drug Development

    Implications for Regulatory Bodies

    Implications for Patients, Healthcare Providers, and Payers

    Conclusions

    References

    Chapter 4. Cancer Epigenetics: From Mechanism to Therapy

    Acknowledgments

    Summary

    Introduction

    Characterizing the Epigenome

    Epigenetics and the Cancer Connection

    Epigenetic Pathways Connected to Cancer

    Perspective and Conclusions

    References

    Chapter 5. Converting Cancer Therapies into Cures: Lessons from Infectious Diseases

    Acknowledgments

    Summary

    Introduction

    Mutational Mechanisms of Resistance

    Nonmutational Resistance Mechanisms

    Overcoming Resistance

    Exceptions: Examples of Successful Monotherapy

    Precision Diagnostics: Essential for Targeted Cancer Drugs, Missed Opportunity for Antibacterials

    Conclusions and Challenges

    References

    Chapter 6. Antibody-Based Immunotherapy of Cancer

    Acknowledgments

    Summary

    Introduction

    Manipulating Antibody Structure

    Stimulating Persistent Immunity

    Modulating the Amplitude of Immune Responses

    Immunoconjugates: Targeting Cytotoxic Agents

    A Longer-Term View

    Supplemental Information

    Web Resources

    References

    Chapter 7. Macrophage Regulation of Tumor Responses to Anticancer Therapies

    Acknowledgments

    Summary

    Introduction

    Tumor-Associated Macrophages

    Macrophage Involvement in Tumor Responses to Therapy

    Concluding Remarks: Implications for Cancer Treatment

    References

    Chapter 8. Recombinant Viral Vaccines for Cancer

    Acknowledgments

    Summary

    Cancer Immunity

    Recombinant Viral Vaccines Expressing TAAs

    Recombinant Viral Vaccines Expressing Tumour-Associated Antigens and Immunomodulatory Molecules

    IT Vaccination to Enhance Immune Activation

    Oncolytic Viral Vaccines

    Granulocyte Macrophage Colony Stimulating Factor

    Modulating the Tumour Immune Microenvironment

    Implications for the Future of Cancer Vaccines

    References

    Chapter 9. Dynamics of Targeted Cancer Therapy

    Summary

    Targeted Cancer Therapy

    Modeling the Evolution of Resistance to Cancer Therapy

    Effects of Density Dependence on the Evolution of Resistance

    Applications and Extensions

    Concluding Remarks and Future Perspectives

    Appendix A Supplementary Material

    References

    Chapter 10. Targeting Protein–Protein Interactions as an Anticancer Strategy

    Acknowledgment

    Summary

    Rising Interest in Targeting PPIs

    PPI interfaces Constitute Basic Units in Oncogenic Signaling Networks

    OVERCOMING CHALLENGES and Current Strategies for Targeting of PPIs

    Clinical Validation of PPI Targeting in Cancer

    Emerging Opportunities for Targeting of PPIs

    Concluding Remarks

    References

    Chapter 11. Targeting the RAS Pathway in Melanoma

    Acknowledgments

    Summary

    Current Therapies for Melanoma

    The Central Melanoma Axis and Therapeutic Targets

    Concluding Remarks

    References

    Chapter 12. Targeting Tumor Cell Motility as a Strategy against Invasion and Metastasis

    Acknowledgments

    Summary

    Basic Mechanisms of Tumor Dissemination

    Motility Cascade

    Extracellular Regulators of Migration

    Potential Interventional Opportunities

    Concluding Remarks

    References

    Chapter 13. The Valley of Death in Anticancer Drug Development: A Reassessment

    Acknowledgments

    Summary

    The Valley of Death

    The Tumor Microenvironment

    The Impact of Exposure Time

    Choice of Preclinical Model

    Drug Delivery to Tumors

    Changing Clinical Practice

    Some Paths Forward

    Concluding Remarks

    References

    Chapter 14. Metformin and Cancer: From the Old Medicine Cabinet to Pharmacological Pitfalls and Prospects

    Acknowledgments

    Summary

    The Past and Present of Metformin

    Rationale for Cancer Prevention with Metformin

    Role of Metformin in Gluconeogenesis and its Link to Chemoprevention

    Influence of Metformin Disposition on Cancer Prevention

    Concluding Remarks

    References

    Chapter 15. Curing APL through PML/RARA Degradation by As2O3

    Acknowledgments

    Summary

    Both Poison and Cure

    APL Response to Therapies

    A Key Role of PML/RARA Degradation in Therapy Response

    How does Arsenic Induce Degradation of PML and PML/RARA?

    How does Arsenic Trigger PML Sumoylation?

    What is the Role for PML NBs in APL Therapy?

    Are there Other Arsenic-Sensitive Diseases?

    Concluding Remarks

    References

    Glossary

    Chapter 16. A Snapshot of Chemoresistance to PARP Inhibitors

    Acknowledgments

    Summary

    Exploiting Synthetic Lethality for Targeted Therapy

    PIR: Experimental and Clinical Evidence

    Restoration of BRCA Function: an Inevitable Drawback of PARPi?

    P-Glycoprotein Upregulation: Auto-Defeating Effects of PARPi

    Further Considerations

    Concluding Remarks

    References

    Index

Product details

  • No. of pages: 322
  • Language: English
  • Copyright: © AP Cell 2013
  • Published: December 10, 2013
  • Imprint: AP Cell
  • eBook ISBN: 9780127999173
  • Paperback ISBN: 9780124201927

About the Editor

Cell Press

Affiliations and Expertise

Cell, Cancer Cell, Trends in Molecular Medicine, Trends in Genetics, Trends in Pharmaceutical Sciences

Ratings and Reviews

Write a review

There are currently no reviews for "Cell Press Reviews: Cancer Therapeutics"